Neuralink took a huge step closer to human trials. Scientists have lots of nervous questions.
Noah KirschWealth And Power Reporter
Published Jan. 25, 2022 11:58AM ET
IBR Executive Director Dr James Giordano comments on these human trials.
Neuralink took a huge step closer to human trials. Scientists have lots of nervous questions.
Noah KirschWealth And Power Reporter
Published Jan. 25, 2022 11:58AM ET
IBR Executive Director Dr James Giordano comments on these human trials.